Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells

Oncology Research

Volumn 10, Issue 11-12, 1998, Pages 595-603

  Luo, Feng R ^a   Wyrick, Steven D ^b   Chaney, Stephen G ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cellular biotransformation; Cytotoxicity; Oxilaplatin

Indexed keywords

ANTINEOPLASTIC AGENT; OXALIPLATIN; PLATINUM; PLATINUM COMPLEX;

ARTICLE; BIOTRANSFORMATION; CARCINOMA; CELL CULTURE; COLON TUMOR; COMPARATIVE STUDY; DNA ADDUCT; DRUG EFFECT; HUMAN; METABOLISM;

ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CARCINOMA; COLONIC NEOPLASMS; DNA ADDUCTS; HUMANS; ORGANOPLATINUM COMPOUNDS; PLATINUM; TUMOR CELLS, CULTURED;

EID: 0032242652     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Weiss, R. B.; Christian, M. C. New cisplatin analogues in development - a review. Drugs 46:360-377; 1993.
2. Kidani, Y.; Noji, M.; Tashiro, T. Antitumor activity of platinum(II) complexes of 1,2-diaminocyclohexane isomers. Gann 71:637-643; 1980.
3. Mathe, G.: Kidani, Y.; Segiguchi, M.; Eriguchi, M.; Fredj, G.; Peytavin, G.; Misset, J. L.; Brienza, S.; de Vassals, F.; Chenu, E.; Bourut, C. Oxalato-platinum or 1-OHP, a third-generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed. Pharmacother. 43:237-250; 1989.
4. Misset. J. L.; Kidani, Y.; Gastiaburu, J.; Jasmin, C.; Levi, F.; Boughattas, N.; Lemaigre, G.; Caussanel, J. P.; Triana, B. K.; Goldschmidt. E.; Musset, M.; Mauvcmay, R. Y.; Mathe, G. Oxalatoplatinum (1-OHP): Experimental and clinical studies. In: Howell, S. B., ed. Platinum and other metal coordination compounds in cancer chemotherapy. New York: Plenum Press; 1991:369-375.
5. Tashiro, T.; Kawada, Y.; Sakurai, Y.; Kidani, Y. Antitumor activity of a new platinum complex oxalato (trans-1-1,2-diaminocyclohexane)platinum (II): New experimental data. Biomed. Pharmacother. 43:251-260; 1989.
6. Extra, J. M.; Espie, M.; Calvo, F.; Ferme, C.; Mignot, L.; Many, M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol. 25:299-303; 1990.
7. Daley-Yates, P. T.; McBrien, D. C. H. The inhibition of renal ATPase by cisplatin and some biotransformation products. Chem. Biol. Interact. 40:325-334; 1982.
8. Luo, F. R.; Wyrick, S. D.; Chaney, S. G. Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. Cancer Chemother. Pharmacol. (in press).
9. 9. Luo, F. R.; Wyrick, S. D.; Chaney, S. G. Biotransformations of oxaliplatin in rat blood in vitro. J. Biochem. Mol. Toxicol. 13:159-169; 1999.
10. Pendyala, L.; Creaven, P. J. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 53:5970-5976; 1993.
11. Daley-Yates, P. T.; McBrien, D. C. H. Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the ncphrotoxic and antitumour activity of cisplatin. Biochem. Pharmacol. 33:3063-3070; 1984.
12. Shirazi, F. H.; Molepo, J. M.; Stewart, D. J.; Ng, C. E.; Raaphorst, G. P.; Goel, R. Cytotoxicity, accumulation, and efflux of cisplatin and its metabolites in human ovarian carcinoma cells. Toxicol. Appl. Pharmacol. 140:211-218; 1996.
13. Luo, F. R.; Yen, T. Y.; Wyrick, S. D.; Chaney, S. G. High performance liquid Chromatographic separation of the biotransformation products of oxaliplatin. J. Chromatogr. B Biomed. Appl. (in press).
14. 14. Carfagna, P. F.; Poma, A.; Wyrick, S. D.; Holbrook, D. J.; Chaney, S. G. Comparisons of tetrachloro(d,1-trans)1,2-diaminocyclohexane-platinum(IV) biotransformations in the plasma of Fischer 344 rats at therapeutic and toxic doses. Cancer Chemother. Pharmacol. 27:335-341; 1991.
15. Chaney, S. G.; Wyrick, S.; Till, G. K. In vitro biotransformations of tetrachloro(d,1-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma. Cancer Res. 50:4539-1545; 1990.
16. Mauldin, S. K.; Gibbons, G.; Wyrick, S. D.; Chaney, S. G. Intracellular biotransformation of platinum compounds with the 1, 2-diaminocyclohexane carrier ligand in the L1210 cell line. Cancer Res. 48:5136-5144; 1988.
17. Butour, J. L.; Mazard, A. M.; Macquet, J. P. Kinetics of the reaction of cis-platinum compounds with DNA in vitro. Biochem. Biophys. Res. Commun. 133:347-353; 1985.
18. Wyrick, S. D.; Chaney, S. G. Tritiated platinum antitumor agents containing the trans-(d,1)-1,2-diaminocyclohexane carrier ligand. J. Label. Compound Radiopharm. 25:349-357; 1987.
19. Mauldin, S. K.; Plescia, M.; Richard, F. A.; Wyrick, S. D.; Voyksner, R. D.; Chaney, S. G. Displacement of the bidentate malonate ligand from (d,1-trans-1, 2-diaminocyclohexane)malonatoplatinum(II) by physiologically important compounds in vitro. Biochem. Pharmacol. 37:3321-3333; 1988.
20. Chaney, S. G.; Gibbons, G. R.; Wyrick, S. D.; Podhasky. P. An unexpected biotransformation pathway for tetrachloro-(d,1-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line. Cancer Res. 51:969-973; 1991.